Spun out of Massachusetts General Hospital, Mersana Therapeutics, Inc.(NASDAQ; MRSN) is a clinical-stage oncology company engineering novel drug conjugates. The firm went publiic in June 2017. The claim to be "rewriting the rules" for immunoconjugate therapies by leveraging their Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients lives. The Fleximer platform allows customization in design of an Antibody-drug conjugates (ADCs) with specific properties to overcome limitations of current ADC approaches and increase the drugs chances of effectively attacking a particular cancer. The approach is to engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. With safe delivery of higher quantities of therapeutic payloads directly to a tumor, Mersanas ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of todays cancer treatments. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADCs) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top pharma companies to develop next generation Fleximer-ADCs. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. The company focuses on Fleximer, a clinically validated biodegradable polymer that provides benefits for the development of drugs across therapeutic modalities, including small molecules, biologics, antibody-drug conjugates, antibody fragments, and siRNA, as well as synergistic drug combinations. Its products pipeline includes XMT-1001, a novel camptothecin analog conjugate for the treatment of cancer; XMT-1107, a novel anti-angiogenic conjugate for the treatment of tumors; and antibody-drug conjugates, drug therapeutics for cancer treatment. Formerly known as Nanopharma Corp., the name was changed to Mersana Therapeutics, Inc. in November 2005.
